NCT03852446View on ClinicalTrials.gov

Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

March 5, 2018

Study Completion Date

August 14, 2018

Conditions
Healthy
Interventions
DRUG

Indoximod HCL (F2) tablets

The doses will be ascending per cohort from 600 mg to 2400 mg

DRUG

Indoximod base formulation

Single oral administration of 1200 mg

OTHER

Placebo

The matching placebo doses will be ascending per cohort from 1 to 4 tablets

DRUG

Indoximod HCL (F2) tablets

Single oral administration of 1200 mg

Trial Locations (1)

07407

Frontage Clinical Services, Inc., Secaucus

Sponsors
All Listed Sponsors
lead

NewLink Genetics Corporation

INDUSTRY

NCT03852446 - Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter